Carolyn A. Alenci
Associate
Duane Morris LLP
100 High Street, Suite 2400
Boston, MA 02110-1724
USA
Phone: +1 857 488 4240
Fax: +1 857 401 3026
Email: caalenci@duanemorris.com

Carolyn A. Alenci practices in the area of intellectual property litigation. Ms. Alenci is admitted to practice law in Massachusetts, New York and the District of Columbia and is registered to practice before the United States Patent and Trademark Office. She is a cum laude graduate of Franklin Pierce Law Center, where she where she received a joint degree with an emphasis on intellectual property and was managing editor and articles editor of IDEA: The Intellectual Property Law Review. She is a summa cum laude graduate of Auburn University, where she studied chemical engineering.

Areas of Practice

• Intellectual Property Law
• Patents
• Trademarks
• Copyrights
• Litigation

Representative Matters

• Obtained a $65 million plus settlement on behalf of Tekmira Pharmaceuticals Corp. Tekmira had sued Alnylam Pharmaceuticals Inc. and AlCana Technologies, Inc. in the Business Litigation Session of the Massachusetts Superior Court alleging that Alnylam and AlCana misappropriated Tekmira's trade secrets related to gene-silencing therapeutics. In addition to the payments, the settlement also assigns control to Tekmira over its leading systemic RNAi Therapeutics delivery technology, and brings clarity around the ownership of the intellectual property that protects its lipid nanoparticle (LNP) technology.
• Avanir Phamaceuticals, Inc., et al. v. Wockhardt, Ltd., et al., 11-CV-704 (Consolidated) (LPS) (D.Del.) Patent infringement action regarding Wockhardt’s ANDA to make a generic version of Avanir’s PBA product Nuedexta®, the active ingredients of which are dextromethorphan hydrobromide and quinidine hydrobromide.
• Abbott Laboratories v. Sandoz Inc., 10-538 (D.Del. - S. Robinson). Representing Sandoz in litigation regarding NIASPAN®, the active ingredient of which is niacin.
• King Pharmaceuticals, Inc., et al. v. Actavis Inc., et al., Case No. 07-CV-05041 (GEB) (MCA) (D.N.J.). Patent infringement action regarding Actavis' ANDA to make a generic version of King's pain product Avinza®, the active ingredient of which is morphine sulfate.
• Pfizer Inc., et al. v. Mylan Pharmaceuticals, Inc., Case No. 10-CV-00085 (JJF) (D.Del.). Patent infringement action regarding Mylan's ANDA to make a generic version of Pfizer's cardiovascular product Caduet®, the active ingredients of which are atorvastatin calcium and amlodipine besylate.
• Wyeth v. Apotex Inc. and Apotex Corp., No. 08-022308 (S.D. Fla.) Patent infringement action regarding Apotex's ANDA to make a generic version of Wyeth's antidepressant product EFFEXOR XR® (venlafaxine hydrochloride).
• Obtained a settlement for Wockhardt, a global pharmaceutical and biotechnology company, that resolved Hatch-Waxman litigation initiated by Sepracor Inc. seeking to bar Wockhardt from offering a generic version of the blockbuster insomnia medicine Lunesta®. Sepracor agreed to allow Wockhardt entry into the market before the expiration of its Lunesta patents.

Admissions

• Massachusetts
• New York
• U.S. Patent and Trademark Office
• District of Columbia
• U.S. District Court for the District of Massachusetts
• U.S. Court of Appeals for the First Circuit

Education

• Franklin Pierce Law Center, J.D., cum laude, 2009
  - IDEA: The Intellectual Property Law Review, Managing Editor and Articles Editor
• Auburn University, B.C.H.E., summa cum laude, 2006
• Franklin Pierce Law Center, LL.M., Intellectual Property, 2009

Experience

• Duane Morris LLP
  - Associate, 2010-present
• Auburn University Office of Technology Transfer
  - Legal Intern, 2006-2010

Selected Publications

• Co-author, "FDA Issues Guidance for Industry on Generic Drug User Fee Amendments of 2012: Q&A," Duane Morris Alert, August 29, 2012; republished with edits by GenericsWeb INNsight, September 2012
• Co-author, "FDA's Animal Generic Drug User Fee Rates and Payment Procedures for Fiscal Year 2013," Duane Morris Alert, August 8, 2012
• Co-author, "FDA's Guidelines for Petitions Filed Under Section 505(q) of Food, Drug, and Cosmetic Act," Duane Morris Alert, June 16, 2011